News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News AZ, Leo, and Daiichi Sankyo rapped for ad transgressions Leo Pharma, AstraZeneca, and Daiichi Sankyo are the latest drugmakers to fall foul of UK guidelines on advertising of medicines.
News Novo Nordisk suspended from ABPI after code breach The two-year ban reflects "serious breaches” of the trade organisation’s code of practice.
News ABPI code updated with first social media guidance Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.
Views & Analysis New IFPMA and EFPIA guidance on use of social media by the p... On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (I
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face